Effective Doses of Nalbuphine Combined with Propofol in Painless Hysteroscopy.

ED50 ED95 effective dose hysteroscopy nalbuphine propofol

Journal

International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487

Informations de publication

Date de publication:
2022
Historique:
received: 26 03 2022
accepted: 31 05 2022
entrez: 20 6 2022
pubmed: 21 6 2022
medline: 21 6 2022
Statut: epublish

Résumé

Nalbuphine is becoming a common analgesic used in hysteroscopic operations. The aim of this study was to identify the median effective dose (ED50) and 95% effective dose (ED95) of nalbuphine combined with propofol in painless hysteroscopy. Twenty-five patients aged 18-60 years with an American Society of Anesthesiologists classification of I-II who were scheduled for painless hysteroscopy were recruited. The initial dose of nalbuphine was set at 0.15 mg/kg and varied by 0.01 mg/kg according to the Dixon sequential method. The ED50/ED95 of nalbuphine combined with propofol for hysteroscopy was calculated by the probit method. The ED50 of nalbuphine was 0.122 (95% confidence interval (CI) 0.092-0.137) mg/kg, and the ED95 of nalbuphine was 0.153 (95% CI 0.138-0.361) mg/kg. The ED50/ED95 values of nalbuphine combined with propofol in painless hysteroscopy are 0.122 mg/kg and 0.153 mg/kg, respectively. Nalbuphine at 0.153 mg/kg combined with propofol is effective and safe for painless hysteroscopy.

Identifiants

pubmed: 35719419
doi: 10.2147/IJGM.S367449
pii: 367449
pmc: PMC9199904
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5609-5614

Informations de copyright

© 2022 Zhong et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Br J Pharmacol. 2004 Apr;141(8):1331-4
pubmed: 15051626
Pain Ther. 2021 Dec;10(2):1155-1169
pubmed: 34089152
Anesth Analg. 1987 Nov;66(11):1155-64
pubmed: 3499096
Cochrane Database Syst Rev. 2017 Oct 05;(10):CD007710
pubmed: 35611933
Updates Surg. 2020 Dec;72(4):967-976
pubmed: 32008214
Indian J Pharmacol. 2016 Nov-Dec;48(6):617-623
pubmed: 28066096
Chin Med J (Engl). 2018 Nov 20;131(22):2693-2698
pubmed: 30381583
Sci Rep. 2015 Jun 03;5:10927
pubmed: 26039709
Front Pharmacol. 2018 Nov 29;9:1388
pubmed: 30555325
J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):458-60
pubmed: 21547169
Pain Ther. 2020 Dec;9(2):563-571
pubmed: 32748184
Basic Clin Pharmacol Toxicol. 2019 Nov;125(5):460-465
pubmed: 31231918
Pain Ther. 2021 Dec;10(2):1235-1243
pubmed: 34131886
PLoS One. 2017 Dec 12;12(12):e0188901
pubmed: 29232379
Front Pharmacol. 2021 Dec 01;12:673550
pubmed: 34924999

Auteurs

Weiwei Zhong (W)

Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.

Chen Chen (C)

Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.

Weixiang Tang (W)

Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, People's Republic of China.

Classifications MeSH